Research
Hormonal
Omega-3 fatty acid supplementation reduces cardiovascular morbidity and mortality by lowering triglycerides, reducing blood pressure, and decreasing arrhythmia risk.
To protect your heart, aim for at least two servings of fish per week, ensuring one is oily (like salmon or mackerel). If you don't eat fish, consider a fish oil supplement providing around 1g of EPA/DHA daily, especially if you have existing heart conditions. This is a foundational dietary shift, not a quick fix.
LimitedSupportsHIGH confidence
Reduced cardiovascular morbidity and mortality is a well-established benefit of their intake. ... The most compelling evidence for the cardiovascular benefit provided by v-3 FAs comes from an analysis of pooled data from three large controlled trials with 32 000 participants that showed 19–45% reduction in cardiovascular events.
Why this rating
Based on a comprehensive review citing multiple large controlled trials and meta-analyses.
Source
Omega-3 fatty acids: a comprehensive review of their role in health and disease
B M Yashodhara et al. · Postgraduate Medical Journal · 2009
DOI 10.1136/pgmj.2008.073338
narrative_reviewCited 327×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Omega-3 fatty acids reduce plasma triglyceride concentrations by less than 24% and may marginally increase LDL-cholesterol, though LDL particle size increases.Limited
- Maternal intake of Omega-3 fatty acids (specifically DHA) reduces the risk of premature birth and improves fetal intellectual development.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →